CT53518, a novel selective FLT3 antagonist for the sorted by
relevance

Admin17.07.2021

CT53518, a novel selective FLT3 antagonist for the

Admin04.09.2021

CT53518, a novel selective FLT3 antagonist for the

2206
Admin03.09.2021

CT53518, a novel selective FLT3 antagonist for the

1606
Admin26.09.2021

CT53518, a novel selective FLT3 antagonist for the

2401
Admin22.08.2021

CT53518, a novel selective FLT3 antagonist for the

102
Admin01.08.2021

CT53518, a novel selective FLT3 antagonist for the

4805
Admin19.07.2021

CT53518, a novel selective FLT3 antagonist for the

8409
Admin08.09.2021

CT53518, a novel selective FLT3 antagonist for the

9300
Admin25.08.2021

CT53518, a novel selective FLT3 antagonist for the

Admin18.08.2021

CT53518, a novel selective FLT3 antagonist for the

6807
Admin20.08.2021

CT53518, a novel selective FLT3 antagonist for the

2306
Admin27.07.2021

CT53518, a novel selective FLT3 antagonist for the

9600
Admin02.08.2021

CT53518, a novel selective FLT3 antagonist for the

1709
Admin09.09.2021

(PDF) Phase 1 clinical results with tandutinib (MLN518), a

2307
Admin11.09.2021

Relation between inhibition of FLT3 phosphorylation in

1506
Admin31.08.2021

Distribution of KIT mutations in GISTs. | Download

6209
Admin06.09.2021

Flt Inhibition | Flt3 Mutation | Flt Inhibitor Review

6207
Admin25.08.2021

Tandutinib phase 1 experience: patient characteristics

Admin25.09.2021

Tandutinib plasma concentration versus time profile for a

506
Admin18.09.2021

Change in day-28 rate-corrected QT interval (QTc) from

4208
Admin25.09.2021

Risk stratification of primary GIST by mitotic index, size

7601